{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-288498","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.321718+00:00","generated_at":"2026-06-07T18:49:24.811698+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclerion appoints Regina Graul as President; CEO Peter Hecht transitions to strategic consultant","bullets":["Regina Graul, Ph.D., appointed President effective Dec 1, 2023; CEO Peter Hecht steps down but remains strategic consultant and board member.","Graul earns $372K base salary, bonuses up to $125K, and up to 100K restricted shares vesting over time.","Graul previously VP at EQRx and olinciguat program lead at Cyclerion; 15+ years at Ironwood Pharmaceuticals.","Hecht completed transitional assignment; Cyclerion to rebuild with board additions Dina Katabi and Michael Higgins.","Company to evaluate existing assets and pursue external innovation for next phase."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-288498","json":"https://secwatch.observer/filing/0001193125-23-288498.json","markdown":"https://secwatch.observer/filing/0001193125-23-288498.md","text":"https://secwatch.observer/filing/0001193125-23-288498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/d569286d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:49:24.811698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99e05332b0","claim":"Regina Graul was elected as President at Cyclerion Therapeutics, Inc..","evidence_excerpt":"On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) unanimously elected Regina Graul Ph.D., as President of the Company, effective December 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"d48c0e03ee","claim":"Peter Hecht resigned as President and Chief Executive Officer at Cyclerion Therapeutics, Inc..","evidence_excerpt":"She replaces Peter Hecht, Ph.D., who resigned on November 30, 2023 as President and Chief Executive Officer to pursue his responsibilities as President of Tisento.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}